Vantage Consulting Group Inc
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 12, 2025), Vantage Consulting Group Inc reported 5 stock positions worth $10.5 million. Its top holding was Babcock & Wilcox Enterpr (BW) at 37.8% of the portfolio, followed by Cibus (CBUS, 30.3%) and Adc Therapeutics (ADCT, 16.1%). Compared with Q3 2024, it opened 1 new position. The biggest buy was a new position in Potbelly (PBPB).
- Most Recent 13F
- Q4 2025
- Location
- VIRGINIA BEACH, VA
- CIK
- 0001843547
- Portfolio Value
- $10.5M (Q4 2024)
- SEC Filing
- 0001843547-25-000004 ↗ filed Feb 12, 2025
Holdings Value
Holdings 5 stocks · $10.5M
| BW Babcock & Wilcox Enterpr | 37.77% | 2,416,200 | $4.0M | No change |
| CBUS Cibus Inc. | 30.31% | 1,143,949 | $3.2M | No change |
| ADCT Adc Therapeutics SA | 16.14% | 850,737 | $1.7M | No change |
| PBPB Potbelly Corp. | 14.80% | 164,875 | $1.6M | New |
| FIBROGEN INC | 0.99% | 195,707 | $104K | No change |
Portfolio Sells Q3 2024 → Q4 2024
| None this quarter. | |||
Portfolio Buys Q3 2024 → Q4 2024
| PBPB Potbelly Corp. | New | 14.80% | +14.80 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q4 2025 | 3 | $19.7M | BW, ADCT, CBUS |
| Q3 2025 | 3 | $11.2M | BW, ADCT, CBUS |
| Q2 2025 | 3 | $5.7M | BW, ADCT, CBUS |
| Q1 2025 | 4 | $5.0M | CBUS, BW, ADCT, FIBROGEN INC |
| Q4 2024 | 5 | $10.5M | BW, CBUS, ADCT, PBPB, FIBROGEN INC |
| Q3 2024 | 4 | $11.4M | BW, CBUS, ADCT, FIBROGEN INC |
| Q2 2024 | 191 | $134.6M | SYNTAX STRATIFIED LARGE CAP, CBUS, SMDY, BW, SSLY |
| Q1 2024 | 212 | $157.3M | SYNTAX STRATIFIED LARGE CAP, CBUS, SMDY, ADCT, SSLY |